I struggle to see how NYR beats Merck to market. If I'm not mistaken, Merck had similar efficacy as Nyrada's asset did preclinically, but actually in humans in their Phase I trials. Probably puts them about 2 years ahead? Returns should be there though as you said!
Ann: Investor Roadshow Presentation, page-4
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
-0.001(1.00%) |
Mkt cap ! $18.03M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.9¢ | $28.89K | 289.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 73984 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 127592 | 3 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| NYR (ASX) Chart |